Nearly 2 billion people worldwide and 100 million people in the US are affected by a brain or nervous system disorder including addiction, Alzheimer’s, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinson’s disease, sensory disorders, stroke, traumatic brain injury, obesity, sensory disorders and sleep disorders. Therapeutic devices are stepping in where pharmaceuticals have failed to provide solutions. Venture and corporate investors have provided over $3 billion in investment to private neurodevice companies over the past seven years. These investments have sometimes produced lucrative exits and sometimes utter failures. Find out about the next wave of neurodevices in development, the competitive landscape, the market opportunities and the return on investment potential in 130 page The Neurodevice 2012 Report.